Key result
JAM-A mRNA was elevated in patients with untreated hypertension compared with normotensive patients, and its upregulation preceded stable elevation of arterial pressure in rat models.
Why the study?
Does junctional adhesion molecule-A (JAM-A) expression correlate with and contribute to the progression of hypertension?
Observational
Does junctional adhesion molecule-A (JAM-A) expression correlate with and contribute to the progression of hypertension?
JAM-A upregulation precedes stable elevation of arterial pressure and may serve as a novel prognostic marker and pathogenic factor in hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for JAM-A as hypertension marker; prospective studies needed before any clinical role.
AIMS: Establishing biochemical markers of pre-hypertension and early hypertension could help earlier diagnostics and therapeutic intervention. We assess dynamics of junctional adhesion molecule-A (JAM-A) expression in rat models of hypertension and test whether JAM-A expression could be driven by angiotensin (ANG) II and whether JAM-A contributes to the progression of hypertension. We also compare JAM-A expression in normo- and hypertensive humans. METHODS AND RESULTS: In pre-hypertensive and spontaneously hypertensive rats (SHRs), JAM-A protein was overexpressed in the brainstem microvasculature, lung, liver, kidney, spleen, and heart. JAM-A upregulation at early and late stages was even greater in the stroke-prone SHR. However, JAM-A was not upregulated in leucocytes and platelets of SHRs. In Goldblatt 2K-1C hypertensive rats, JAM-A expression was augmented before any increase in blood pressure, and similarly JAM-A upregulation preceded hypertension caused by peripheral and central ANG II infusions. In SHRs, ANG II type 1 (AT(1)) receptor antagonism reduced JAM-A expression, but the vasodilator hydralazine did not. Body-wide downregulation of JAM-A with Vivo-morpholinos in juvenile SHRs delayed the progression of hypertension. In the human saphenous vein, JAM-A mRNA was elevated in hypertensive patients with untreated hypertension compared with normotensive patients but reduced in patients treated with renin-angiotensin system antagonists. CONCLUSION: Body-wide upregulation of JAM-A in genetic and induced models of hypertension in the rat precedes the stable elevation of arterial pressure. JAM-A upregulation may be triggered by AT(1) receptor-mediated signalling. An association of JAM-A with hypertension and sensitivity to blockers of ANG II signalling were also evident in humans. We suggest a prognostic and possibly a pathogenic role of JAM-A in arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2012) conducted an observational in Hypertension. JAM-A upregulation vs. Normotensive state or renin-angiotensin system antagonist treatment was evaluated on JAM-A expression levels. JAM-A mRNA was elevated in patients with untreated hypertension compared with normotensive patients, and its upregulation preceded stable elevation of arterial pressure in rat models.
Synapse has enriched 10 related papers. Consider them for comparative context: